Skip to main content

Hausfeld Announces $55 Million Settlement in Antitrust Class Action Against Celgene

Related Lawyers: Brent W. Landau, Melinda R. Coolidge, Walter D. Kelley Jr., Katie R. Beran, Tamara Freilich
Related Practice Areas: Antitrust / Competition

Hausfeld announced today that it has reached a $55 million settlement with Celgene Corporation in a long-running class action, In re Thalomid and Revlimid Antitrust Litigation. The settlement is one of the largest pharmaceutical settlements on behalf of end payors (consumers, insurers, union health and welfare funds, municipalities, and others) in an antitrust case in the last decade.

According to Melinda Coolidge, Partner at Hausfeld, “Cancer patients shouldn’t have to worry about the rising cost of their life-saving medications. We are very pleased to have achieved such a sizable settlement on behalf of those who have shouldered the cost of these drugs.”

Hausfeld brought this class action suit in 2014, alleging that Celgene had monopolized the market for two drugs, Thalomid and Revlimid, which are primarily used to treat multiple myeloma, a cancer that forms in the blood. Throughout the litigation, the end payor plaintiffs asserted that prices for the two drugs were higher than they would have been in a competitive market.

Following the close of discovery and during the pendency of the plaintiffs’ motion to certify the class, the parties agreed to resolve the case. Any person or entity that paid for some or all of the purchase price of Thalomid or Revlimid in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, or Tennessee, for use by themselves, their families, or their members, employees, insureds, participants, or beneficiaries, will be invited to file a claim to participate in the settlement.

Hausfeld attorneys working on this case include Melinda Coolidge, Walter Kelley, Brent Landau, Katie Beran, and Tamara Freilich. The other lead counsel in the case were Block & Leviton LLP, and Hach, Rose, Schirripa & Cheverie LLP.

For further information or to arrange interviews please contact:

Melinda Coolidge

mcoolidge@hausfeld.com
202-540-7144

NOTES TO EDITORS

About Hausfeld

Hausfeld is a leading global law firm with offices in Berlin, Boston, Brussels, Düsseldorf, London, New York, Paris, Philadelphia, San Francisco, Stockholm, and Washington, DC. The firm has a broad range of complex litigation expertise, particularly in antitrust/competition, financial services, sports and entertainment, environmental, mass torts, consumer protection, and human rights matters, often with an international dimension. Hausfeld aims to achieve the best possible results for clients through its practical and commercial approach, avoiding litigation where feasible, yet litigating robustly when necessary. Hausfeld’s extensive experience with alternative and innovative fee models offers clients a diverse menu of engagement options and maximum flexibility in terms of managing their cost exposure.

Hausfeld is the only claimants’ firm to be ranked by the Legal 500 and Chambers & Partners as a top tier firm in private enforcement of antitrust/competition law in both the United States and Europe. For more information about the firm, including recent trial victories and landmark settlements, please visit www.hausfeld.com.